Biological therapeutics are widely used in Crohn’s disease, with evidence of efficacy from randomised trials and real-world experience. Primary non-response is a common, poorly understood problem. We aimed to assess blood methylation as a predictor of response to adalimumab, vedolizumab, or ustekinumab in patients with Crohn’s disease.
Published on The Lancet Gastroenterology & Hepatology